Your browser doesn't support javascript.
loading
Risk factors and clinical outcomes for Clostridioides difficile infections in a case control study at a large cancer referral center in Mexico.
De-la-Rosa-Martinez, Daniel; Rivera-Buendía, Frida; Cornejo-Juárez, Patricia; García-Pineda, Bertha; Nevárez-Luján, Carolina; Vilar-Compte, Diana.
Afiliación
  • De-la-Rosa-Martinez D; Instituto Nacional de Cancerologia, Department of Infectious Diseases, Mexico City, Mexico.
  • Rivera-Buendía F; Instituto Nacional de Cancerologia, Department of Infectious Diseases, Mexico City, Mexico.
  • Cornejo-Juárez P; Instituto Nacional de Cancerologia, Department of Infectious Diseases, Mexico City, Mexico.
  • García-Pineda B; Instituto Nacional de Cancerologia, Department of Infectious Diseases, Mexico City, Mexico.
  • Nevárez-Luján C; Instituto Nacional de Cancerologia, Department of Infectious Diseases, Mexico City, Mexico.
  • Vilar-Compte D; Instituto Nacional de Cancerologia, Department of Infectious Diseases, Mexico City, Mexico. Electronic address: diana_vilar@yahoo.com.mx.
Am J Infect Control ; 50(11): 1220-1225, 2022 Nov.
Article en En | MEDLINE | ID: mdl-35172185
ABSTRACT

INTRODUCTION:

Clostridioides difficile infection (CDI) is recognized as the leading cause of nosocomial diarrhea. This study describes CDI's clinical characteristics, risk factors, and outcomes in the cancer population.

METHODS:

We conducted a case-control study on cancer patients from 2015-2018 at the Instituto Nacional de Cancerologia in Mexico. CDI case was defined as diarrhea episode and positive polymerase chain reaction (PCR) for toxigenic strains. Controls were cancer diagnosis-matched patients with diarrhea and negative PCR. Healthcare Facility-Onset (HO-CDI) and Community-Onset, Healthcare Facility-Associated (CO-HCFA-CDI) rates were calculated. For assessing associations, univariate and multivariate logistic regression analyses were conducted.

RESULTS:

We included 148 CDI cases and 148 controls. The CDI rate was 4.1 per 10,000 patient-days and 2.1 per 1,000 patient admissions for HO-CDI and CO-HCFA-CDI episodes, respectively. Clinical characteristics associated with CDI were fever, abdominal pain, and ≥4 episodes of diarrhea/24h. Previous use of proton pump inhibitors (P=.003), fluoroquinolones (P=.016), and cephalosporins (P=.026) increased the risk for CDI acquisition, while higher age (P=.022) and male gender (P=.015) were related to severe episodes. Thirty-day all-cause mortality was higher among CDI patients (18%) than controls (9%).

CONCLUSION:

The CDI rate was lower compared to other series. The incidence of CO-HCFA-CDI episodes increased, and HO-CDI cases decreased from 2016 to 2018. Risk factors for acquisition and severe infection were similar to those reported in non-cancer populations.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies País/Región como asunto: Mexico Idioma: En Revista: Am J Infect Control Año: 2022 Tipo del documento: Article País de afiliación: México

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies País/Región como asunto: Mexico Idioma: En Revista: Am J Infect Control Año: 2022 Tipo del documento: Article País de afiliación: México